Loading...

We've got a brand new version of Simply Wall St! Try it out

Cannabis Growth Opportunity

CNSX:CGOC
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CGOC
CNSX
CA$21M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Cannabis Growth Opportunity Corporation is a principal investment firm. The last earnings update was 86 days ago. More info.


Add to Portfolio Compare Print
  • Cannabis Growth Opportunity is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
  • Cannabis Growth Opportunity has significant price volatility in the past 3 months.
CGOC Share Price and Events
7 Day Returns
-8.2%
CNSX:CGOC
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-26%
CNSX:CGOC
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
CGOC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cannabis Growth Opportunity (CGOC) -8.2% -12.4% -25.6% -26% - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • CGOC outperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • CGOC underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Cannabis Growth Opportunity undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cannabis Growth Opportunity. This is due to cash flow or dividend data being unavailable. The share price is CA$1.34.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cannabis Growth Opportunity's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cannabis Growth Opportunity's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:CGOC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$1.41
CNSX:CGOC Share Price ** CNSX (2019-09-19) in CAD CA$1.34
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cannabis Growth Opportunity.

CNSX:CGOC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:CGOC Share Price ÷ EPS (both in CAD)

= 1.34 ÷ 1.41

0.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannabis Growth Opportunity is good value based on earnings compared to the CA Pharmaceuticals industry average.
  • Cannabis Growth Opportunity is good value based on earnings compared to the Canada market.
Price based on expected Growth
Does Cannabis Growth Opportunity's expected growth come at a high price?
Raw Data
CNSX:CGOC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cannabis Growth Opportunity, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cannabis Growth Opportunity's assets?
Raw Data
CNSX:CGOC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$3.61
CNSX:CGOC Share Price * CNSX (2019-09-19) in CAD CA$1.34
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:CGOC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:CGOC Share Price ÷ Book Value per Share (both in CAD)

= 1.34 ÷ 3.61

0.37x

* Primary Listing of Cannabis Growth Opportunity.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannabis Growth Opportunity is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Cannabis Growth Opportunity's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cannabis Growth Opportunity has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cannabis Growth Opportunity expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannabis Growth Opportunity has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cannabis Growth Opportunity expected to grow at an attractive rate?
  • Unable to compare Cannabis Growth Opportunity's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cannabis Growth Opportunity's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Cannabis Growth Opportunity's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:CGOC Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:CGOC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:CGOC Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 23 -2 22
2019-01-31 12 -33 12
2018-10-31 6 -36 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cannabis Growth Opportunity is high growth as no earnings estimate data is available.
  • Unable to determine if Cannabis Growth Opportunity is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:CGOC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cannabis Growth Opportunity Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CGOC Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 1.41
2019-01-31 0.77
2018-10-31 0.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cannabis Growth Opportunity will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Cannabis Growth Opportunity is trading at Cannabis Growth Opportunity'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Cannabis Growth Opportunity's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Cannabis Growth Opportunity's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cannabis Growth Opportunity's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cannabis Growth Opportunity has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cannabis Growth Opportunity performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cannabis Growth Opportunity's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Unable to establish if Cannabis Growth Opportunity's year on year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
  • Unable to compare Cannabis Growth Opportunity's 1-year earnings growth to the 5-year average as it has been trading publicly for less than 3 years.
  • Cannabis Growth Opportunity has been loss making too recently or no data is available, we can't compare it to the CA Pharmaceuticals industry average.
Earnings and Revenue History
Cannabis Growth Opportunity's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cannabis Growth Opportunity Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CGOC Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 23.49 22.10 1.75
2019-01-31 12.18 11.94 1.63
2018-10-31 5.99 3.48 2.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Cannabis Growth Opportunity has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Cannabis Growth Opportunity used its assets more efficiently than the CA Pharmaceuticals industry average last year based on Return on Assets.
  • Unable to establish if Cannabis Growth Opportunity improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Cannabis Growth Opportunity's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cannabis Growth Opportunity has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cannabis Growth Opportunity's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cannabis Growth Opportunity's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cannabis Growth Opportunity is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cannabis Growth Opportunity has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cannabis Growth Opportunity's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cannabis Growth Opportunity has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cannabis Growth Opportunity Company Filings, last reported 4 months ago.

CNSX:CGOC Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 55.46 0.00 57.01
2019-01-31 47.69 0.03 47.88
2018-10-31 41.47 0.35 41.47
  • Cannabis Growth Opportunity has no debt.
  • Cannabis Growth Opportunity currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • Cannabis Growth Opportunity has no debt, it does not need to be covered by operating cash flow.
  • Cannabis Growth Opportunity has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Cannabis Growth Opportunity's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cannabis Growth Opportunity has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cannabis Growth Opportunity's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cannabis Growth Opportunity dividends.
If you bought CA$2,000 of Cannabis Growth Opportunity shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cannabis Growth Opportunity's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cannabis Growth Opportunity's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:CGOC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cannabis Growth Opportunity has not reported any payouts.
  • Unable to verify if Cannabis Growth Opportunity's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cannabis Growth Opportunity's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cannabis Growth Opportunity has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cannabis Growth Opportunity's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cannabis Growth Opportunity afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cannabis Growth Opportunity has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cannabis Growth Opportunity's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sean Conacher
TENURE AS CEO 0 years
CEO Bio

Mr. Sean Conach has been Director and Acting Chief Executive Officer of Cannabis Growth Opportunity Corporation since September 03, 2019. Mr. Conacher is currently the CEO and founder of GCI Corporation. Mr. Conacher is an experienced CEO with a demonstrated history of working in the financial services and marketing sectors. He is skilled in entrepreneurship, venture capital, public and private equity, foreign exchange, options and asset management.

CEO Compensation
  • Insufficient data for Sean to compare compensation growth.
  • Insufficient data for Sean to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Jamie Blundell

TITLE
President
COMPENSATION
CA$525K
AGE
50

Paul Andersen

TITLE
CFO & Director
COMPENSATION
CA$388K
AGE
52

Michael Campbell

TITLE
Public Markets Portfolio Manager
COMPENSATION
CA$379K
AGE
48
TENURE
1.7 yrs

Sean Conacher

TITLE
Acting CEO & Director
Board of Directors Tenure

Average tenure and age of the Cannabis Growth Opportunity board of directors in years:

1.8
Average Tenure
52
Average Age
  • The average tenure for the Cannabis Growth Opportunity board of directors is less than 3 years, this suggests a new board.
Board of Directors

Gary Yeoman

TITLE
Chairman
COMPENSATION
CA$108K
AGE
64

Jamie Blundell

TITLE
President
COMPENSATION
CA$525K
AGE
50
TENURE
1.8 yrs

Paul Andersen

TITLE
CFO & Director
COMPENSATION
CA$388K
AGE
52
TENURE
1.8 yrs

Sean Conacher

TITLE
Acting CEO & Director

John Durfy

TITLE
Independent Director
COMPENSATION
CA$108K
AGE
53
TENURE
1.8 yrs

Brayden Sutton

TITLE
Independent Director
COMPENSATION
CA$108K
AGE
34
TENURE
1.8 yrs

Nick Richards

TITLE
Independent Director
COMPENSATION
CA$108K
AGE
52
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
31. Oct 18 Buy John Durfy Individual 30. Oct 18 30. Oct 18 3,200 CA$1.31 CA$4,192
X
Management checks
We assess Cannabis Growth Opportunity's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cannabis Growth Opportunity has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cannabis Growth Opportunity Corporation is a principal investment firm. The firm seeks to invest in cannabis industry. It also invests in public cannabis companies. The firm employs fundamental analysis along with a combination of bottom-up and top-down stock picking approach to create its portfolios. Cannabis Growth Opportunity Corporation is based in Toronto, Canada.

Details
Name: Cannabis Growth Opportunity Corporation
CGOC
Exchange: CNSX
Founded:
CA$20,787,756
15,513,251
Website: http://www.cgocorp.com
Address: Cannabis Growth Opportunity Corporation
240 Richmond Street West,
Suite 4163,
Toronto,
Ontario, M5V 1V6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX CGOC Common Shares Canadian National Stock Exchange CA CAD 29. Jan 2018
OTCPK CWWB.F Common Shares Pink Sheets LLC US USD 29. Jan 2018
Number of employees
Current staff
Staff numbers
0
Cannabis Growth Opportunity employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:47
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/06/26
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.